- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07575932
A Study of PF-08653945 and PF-08653944 in Adults With Overweight or Obesity (SOLIS-1) (SOLIS-1)
July 21, 2026 updated by: Pfizer
A PHASE 2B, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, DOSE RANGING, DOSE-FINDING, UMBRELLA STUDY TO EVALUATE EFFICACY AND SAFETY OF PF-08653945 AND PF-08653944, ALONE OR IN COMBINATION, IN ADULTS WITH OVERWEIGHT OR OBESITY (SOLIS-1)
This study is being done to learn about the safety and effects of the study drugs, PF-08653945 and PF-08653944, when given alone or together for weight loss, compared to a placebo (a dummy drug that has no active ingredient in it).
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
872
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Pfizer CT.gov Call Center
- Phone Number: 1-800-718-1021
- Email: ClinicalTrials.gov_Inquiries@pfizer.com
Study Locations
-
-
Nova Scotia
-
Bridgewater, Nova Scotia, Canada, B4V 3N2
- Recruiting
- Viable Clinical Research Corporation
-
-
Ontario
-
Brampton, Ontario, Canada, L6T 0G1
- Recruiting
- Aggarwal and Associates Limited
-
Etobicoke, Ontario, Canada, M9R 4E1
- Recruiting
- Centricity Research Etobicoke Endocrinology
-
London, Ontario, Canada, N5W 6A2
- Recruiting
- Milestone Research Inc.
-
Sarnia, Ontario, Canada, N7T 4X3
- Recruiting
- Bluewater Clinical Research Group Inc.
-
Toronto, Ontario, Canada, M9V 4B4
- Recruiting
- Dr. Anil K. Gupta Medicine Professional Corporation
-
Toronto, Ontario, Canada, M9W 4L6
- Recruiting
- Centricity Research Toronto Manna Multispecialty
-
-
Quebec
-
Chicoutimi, Quebec, Canada, G7H 7K9
- Not yet recruiting
- Ecogene-21
-
Mirabel, Quebec, Canada, J7J 2K8
- Not yet recruiting
- Centricity Research Mirabel Multispecialty
-
Montreal, Quebec, Canada, H1Y 3H5
- Not yet recruiting
- Recherche GCP Research
-
-
-
-
Arizona
-
Chandler, Arizona, United States, 85225
- Recruiting
- Arizona Clinical Trials-Chandler
-
Sun City West, Arizona, United States, 85375
- Recruiting
- Clinical Research Institute of Arizona
-
Tucson, Arizona, United States, 85711
- Recruiting
- Arizona Clinical Trials (ACT) - Tucson
-
-
California
-
Canoga Park, California, United States, 91304
- Recruiting
- San Fernando Valley Health Institute
-
Fountain Valley, California, United States, 92708
- Recruiting
- Ark Clinical Research
-
Garden Grove, California, United States, 92840
- Recruiting
- Paragon Rx Clinical
-
Lomita, California, United States, 90717
- Recruiting
- Torrance Clinical Research Institute, Inc.
-
Long Beach, California, United States, 90815
- Recruiting
- Ark Clinical Research
-
Los Alamitos, California, United States, 90720
- Recruiting
- Collaborative Neuroscience Research, LLC
-
Modesto, California, United States, 95355
- Recruiting
- Paradigm Clinical Research-Modesto
-
San Diego, California, United States, 92108
- Recruiting
- Paradigm Clinical Research Centers, LLC
-
Tustin, California, United States, 92780
- Recruiting
- University Clinical Investigators, Incorporated
-
Walnut Creek, California, United States, 94598
- Recruiting
- Diablo Clinical Research, LLC dba Flourish Research
-
-
Florida
-
Hialeah, Florida, United States, 33012
- Recruiting
- AGA Clinical Trials
-
Jacksonville, Florida, United States, 32205
- Recruiting
- Westside Center for Clinical Research
-
Miami, Florida, United States, 33165
- Recruiting
- New Horizon Research Center
-
Orlando, Florida, United States, 32803
- Recruiting
- Charter Research
-
-
Georgia
-
Atlanta, Georgia, United States, 30318
- Recruiting
- Atlanta Diabetes Associates
-
Stockbridge, Georgia, United States, 30281
- Recruiting
- Clinical Research Atlanta
-
-
Illinois
-
Morton, Illinois, United States, 61550
- Recruiting
- Koch Family Medicine Clinical Research/Elite Research Network
-
Naperville, Illinois, United States, 60540
- Recruiting
- Bioluminux Clinical Research Illinois
-
-
Kansas
-
Lenexa, Kansas, United States, 66219
- Recruiting
- Johnson County Clinical Trials
-
-
Louisiana
-
Mandeville, Louisiana, United States, 70471
- Recruiting
- Delricht Research
-
Prairieville, Louisiana, United States, 70769
- Recruiting
- Delricht Research
-
-
Maryland
-
Lutherville, Maryland, United States, 21093
- Recruiting
- Patient First Clinical Trials (PFCTRIALS)
-
-
Missouri
-
Springfield, Missouri, United States, 65807
- Recruiting
- Delricht Research
-
-
Montana
-
Butte, Montana, United States, 59701
- Recruiting
- Mercury Street Medical Group, PLLC
-
-
Nevada
-
Las Vegas, Nevada, United States, 89119
- Recruiting
- AB Clinical Trials
-
Las Vegas, Nevada, United States, 89128
- Recruiting
- Palm Research Center
-
Las Vegas, Nevada, United States, 89109
- Recruiting
- Alliance Clinical Research Las Vegas (Excel Clinical Research)
-
-
New Jersey
-
Hamilton, New Jersey, United States, 08690
- Recruiting
- Bioluminux Clinical Research
-
-
North Carolina
-
Charlotte, North Carolina, United States, 28210
- Recruiting
- Delricht Research
-
Monroe, North Carolina, United States, 28112
- Recruiting
- Monroe Biomedical Research
-
Statesville, North Carolina, United States, 28625
- Recruiting
- Piedmont Healthcare
-
Wilmington, North Carolina, United States, 28401
- Recruiting
- Accellacare - Wilmington
-
-
Oklahoma
-
Edmond, Oklahoma, United States, 73013
- Recruiting
- Tekton Research, LLC.
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15236
- Recruiting
- Preferred Primary Care Physicians
-
Uniontown, Pennsylvania, United States, 15401
- Recruiting
- Preferred Primary Care Physicians
-
Uniontown, Pennsylvania, United States, 15401
- Recruiting
- Preferred Primary Care Physicians, Inc.
-
-
South Carolina
-
Myrtle Beach, South Carolina, United States, 29572
- Recruiting
- TMA Headlands LLC (d/b/a Trial Management Associates)
-
-
Tennessee
-
Hendersonville, Tennessee, United States, 37075
- Recruiting
- Delricht Research
-
-
Texas
-
Euless, Texas, United States, 76040
- Recruiting
- Cedar Health Research - Euless
-
Houston, Texas, United States, 77040
- Recruiting
- JCCT-JUNO NW Houston
-
Kingwood, Texas, United States, 77339
- Recruiting
- Activian Clinical Research
-
Plano, Texas, United States, 75093
- Recruiting
- 3A Research
-
Prosper, Texas, United States, 75078
- Recruiting
- DelRicht Research @ Zomnir Family Medicine
-
San Antonio, Texas, United States, 78217
- Recruiting
- Worldwide Clinical Trials
-
San Antonio, Texas, United States, 78258
- Recruiting
- Tekton Research, LLC.
-
Shavano Park, Texas, United States, 78231
- Recruiting
- Consano Clinical Research, LLC
-
Tomball, Texas, United States, 77375
- Recruiting
- DM Clinical Research
-
-
Utah
-
Salt Lake City, Utah, United States, 84107
- Recruiting
- Wasatch Clinical Research, LLC
-
Salt Lake City, Utah, United States, 84102
- Recruiting
- Alpine Medical Group
-
-
Virginia
-
Arlington, Virginia, United States, 22206
- Recruiting
- Washington Center for Weight Management and Research
-
Manassas, Virginia, United States, 20110
- Recruiting
- Manassas Clinical Research Center
-
Vienna, Virginia, United States, 22182
- Recruiting
- Delricht Research
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
Eligible participants for this study include:
- adults aged 18 years or older with
- obesity (BMI of 30.0 kg/m2 to 50.0 kg/m2) or with
- overweight (BMI of 27.0 kg/m2 to <30.0 kg/m2) who also have at least 1 prespecified weight-related comorbidity (hypertension, dyslipidemia, cardiovascular disease, or obstructive sleep apnea), at the screening visit.
Exclusion Criteria:
Participants who are not eligible include those with diabetes mellitus, a body weight change of >5% or use of weight loss medications in the 12 weeks prior to screening, a history of or plan for surgical treatment for obesity, and those who are unable or unwilling to comply with contraceptive requirements or are pregnant or lactating.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Cohort 1
Participants receive subcutaneous injections of PF-08653945 or placebo.
|
Subcutaneous Injection
Subcutaneous Injection
|
|
Experimental: Cohort 2
Participants receive subcutaneous injections of PF-08653945 + PF-08653944 or placebo.
|
Subcutaneous Injection
Subcutaneous Injection
Subcutaneous Injection
|
|
Experimental: Cohort 3
Participants receive subcutaneous injections of PF-08653945 + PF-08653944 , PF-08653944 , or placebo.
|
Subcutaneous Injection
Subcutaneous Injection
Subcutaneous Injection
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Percent change from baseline in body weight
Time Frame: Baseline (Week 0) to Week 48
|
Baseline (Week 0) to Week 48
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Percent change from baseline in body weight
Time Frame: Baseline (Week 0) to Week 60
|
Baseline (Week 0) to Week 60
|
|
Change from baseline in body weight
Time Frame: Baseline (Week 0) to Week 48 and Week 60
|
Baseline (Week 0) to Week 48 and Week 60
|
|
Percentage of participants who achieve ≥5% of body weight reduction from baseline
Time Frame: Baseline (Week 0) to Week 48 and Week 60
|
Baseline (Week 0) to Week 48 and Week 60
|
|
Percentage of participants who achieve ≥10% of body weight reduction from baseline
Time Frame: Baseline (Week 0) to Week 48 and Week 60
|
Baseline (Week 0) to Week 48 and Week 60
|
|
Percentage of participants who achieve ≥15% of body weight reduction from baseline
Time Frame: Baseline (Week 0) to Week 48 and Week 60
|
Baseline (Week 0) to Week 48 and Week 60
|
|
Percentage of participants who achieve ≥20% of body weight reduction from baseline
Time Frame: Baseline (Week 0) to Week 48 and Week 60
|
Baseline (Week 0) to Week 48 and Week 60
|
|
Percentage of participants who achieve ≥25% of body weight reduction from baseline
Time Frame: Baseline (Week 0) to Week 48 and Week 60
|
Baseline (Week 0) to Week 48 and Week 60
|
|
Number of participants with treatment emergent adverse events (TEAEs) and serious adverse events (SAEs)
Time Frame: Up to Week 70
|
Up to Week 70
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Pfizer CT.gov Call Center, Pfizer
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 11, 2026
Primary Completion (Estimated)
August 4, 2027
Study Completion (Estimated)
January 5, 2028
Study Registration Dates
First Submitted
May 4, 2026
First Submitted That Met QC Criteria
May 4, 2026
First Posted (Actual)
May 8, 2026
Study Record Updates
Last Update Posted (Actual)
July 22, 2026
Last Update Submitted That Met QC Criteria
July 21, 2026
Last Verified
July 1, 2026
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- C6511002
- SOLIS-1 (Other Identifier: Alias Study Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
Pfizer will provide access to individual de-identified participant data and related study documents (e.g.
protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions.
Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Obesity
-
Dr. Christopher McGowanRecruitingObesity Prevention | Obesity Recidivism | Obesity and Overweight | Obesity and Obesity-related Medical ConditionsUnited States
-
Central Hospital, Nancy, FranceNot yet recruiting
-
Helsinki University Central HospitalKarolinska Institutet; Folkhälsan Researech CenterEnrolling by invitation
-
Istanbul Medipol University HospitalMedipol UniversityCompletedObesity, Morbid | Obesity, Adolescent | Obesity, Abdominal | Weight, Body | Obesity, VisceralTurkey
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; Pennington Biomedical Research... and other collaboratorsCompletedOvernutrition | Nutrition Disorders | Overweight | Body Weight | Pediatric Obesity | Body Weight Changes | Childhood Obesity | Weight Gain | Adolescent Obesity | Obesity, Childhood | Overweight and Obesity | Overweight or Obesity | Overweight AdolescentsUnited States
-
Queen Fabiola Children's University HospitalNot yet recruitingMorbid Obesity | Adolescent Obesity | Bariatric SurgeryBelgium
-
The Hospital for Sick ChildrenCompleted
-
Ihuoma EneliCompletedObesity, ChildhoodUnited States
-
Dr. Christopher McGowanRecruitingObesity Prevention | Obesity Recidivism | Obesity and Overweight | GLP-1 | Obesity and Obesity-related Medical Conditions | Ablation TechniquesUnited States
-
Azienda Ospedaliero-Universitaria Consorziale Policlinico...Institute of Biomembranes, Bioenergetics and Molecular Biotechnologies; Istituti... and other collaboratorsCompletedMorbid Obesity | Metabolically Healthy ObesityItaly
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AkesoNot yet recruitingAtopic DermatitisChina
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States